Latest Migraine surgery Stories
SILVER SPRING, Md., Oct. 15 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Botox injection (onabotulinumtoxinA) to prevent headaches in adult patients with chronic migraine.
The combination of preventive medication and behavioral changes offered significant relief for 77 percent of the individuals enrolled in a study aimed at combating frequent, disabling migraine headaches.
For severe migraine sufferers, psychological treatments build on the benefits of drug therapy.
A preliminary study suggests the same type of botulinum injection used for cosmetic purposes may be associated with reduced frequency of migraine headaches that are described as crushing, vicelike or eye-popping (ocular), but not pain that is experienced as a buildup of pressure inside the head.
MOUNTAIN VIEW, Calif., Oct. 29 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc.
The disability from migraine headaches is an enormous health burden affecting over 30 million Americans.
Migraine headaches are a drain â€” not only on the estimated 30 million Americans who suffer from them, but on the economy, too. Because pain and other symptoms caused by migraine headaches can be quite severe
JENA, Germany, May 12 /PRNewswire/ -- Occlutech, the leading European developer of septum occluders, today announced that it has obtained CE mark approval for its new generation ASD and PFO occluders, the Figulla Flex. The Figulla Flex ASD and PFO occluders encompass a new innovative delivery system, making the use of a threaded hub unnecessary.
A simple procedure may be the key to relief for some who suffer from frequent and severe migraine headaches.
Reducing the frequency and severity of disabling migraines is crucial for quality of life. A new study, published in the February 2009 issue of JACC: Cardiovascular Interventions, finds significant improvement of migraine following catheter-based closure of patent foramen ovale (PFO)â€”a slight opening in the wall between the right and left atria.